Mebendazole
DIPG
Julie KrystalSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the DIPG cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 Meyer Children's Hospital IRCCS | Phase 2 | CCC |
Carboplatin Julie Krystal | Phase 1/2 | CCC |
Oxodotreotide Fundación de investigación HM | Phase 1/2 | CCC |
Olaparib Fundación de investigación HM | Phase 1/2 | CCC |
Incb7839 Pediatric Brain Tumor Consortium | Phase 1 | CC |
iopofosine (¹³¹I) Cellectar Biosciences, Inc. | Phase 1 | CC |
Same molecule, other indications
Mebendazole is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →